Clinical Trial Update: A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care [Phase 3]

View source ↗

Summary

A Phase III study comparing JSKN016 to physician's choice in patients with triple-negative breast cancer who have failed standard of care is currently recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• JSKN016

Snippet

Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Conditions: Triple Negative Breast Cancer | Phase 3 | Status: RECRUITING